M.C. Liu

1.1k total citations · 1 hit paper
7 papers, 490 citations indexed

About

M.C. Liu is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, M.C. Liu has authored 7 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pathology and Forensic Medicine. Recurrent topics in M.C. Liu's work include Cancer Genomics and Diagnostics (5 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Cells and Metastasis (3 papers). M.C. Liu is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Cells and Metastasis (3 papers). M.C. Liu collaborates with scholars based in United States, Italy and Australia. M.C. Liu's co-authors include Rita Nanda, Anne Armstrong, Eric P. Winer, Kenji Tamura, Deborah Toppmeyer, Hirofumi Mukai, L Ryvo, Peter Schmid, Yu Ding and Vassiliki Karantza and has published in prestigious journals such as Cancer Research, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

M.C. Liu

4 papers receiving 486 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.C. Liu United States	3	418	159	158	126	79	7	490
L Ryvo Israel	5	462 1.1×	167 1.1×	173 1.1×	140 1.1×	95 1.2×	8	544
M. Nechaeva Russia	8	326 0.8×	104 0.7×	164 1.0×	100 0.8×	57 0.7×	17	401
Travis Y. Tu United States	7	313 0.7×	251 1.6×	71 0.4×	73 0.6×	99 1.3×	8	449
Zul Fazreen Singapore	6	282 0.7×	167 1.1×	122 0.8×	52 0.4×	72 0.9×	8	391
A. Swat Switzerland	4	305 0.7×	89 0.6×	135 0.9×	112 0.9×	45 0.6×	6	354
Xianping Yi China	4	476 1.1×	143 0.9×	342 2.2×	160 1.3×	195 2.5×	9	680
Sara Jansson Sweden	8	374 0.9×	123 0.8×	92 0.6×	209 1.7×	132 1.7×	13	491
Jean‐Nicolas Lodewyckx Belgium	4	351 0.8×	277 1.7×	63 0.4×	56 0.4×	86 1.1×	7	455
Trine Lindsted United States	7	254 0.6×	86 0.5×	158 1.0×	91 0.7×	208 2.6×	10	439
Katrin Almstedt Germany	12	270 0.6×	95 0.6×	95 0.6×	119 0.9×	125 1.6×	33	403

Countries citing papers authored by M.C. Liu

Since Specialization

Citations

This map shows the geographic impact of M.C. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.C. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.C. Liu more than expected).

Fields of papers citing papers by M.C. Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.C. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.C. Liu. The network helps show where M.C. Liu may publish in the future.

Co-authorship network of co-authors of M.C. Liu

This figure shows the co-authorship network connecting the top 25 collaborators of M.C. Liu. A scholar is included among the top collaborators of M.C. Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.C. Liu. M.C. Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Wolf, Denise M., Amrita Basu, Lamorna Brown Swigart, et al.. (2024). Abstract A002: Serum levels of immune markers associated with pathological complete response (pCR) and immune-related adverse events (irAEs) in early-stage breast cancer patients receiving immune checkpoint inhibitor plus chemotherapy in the I-SPY 2 trial. Cancer Research. 84(3_Supplement_1). A002–A002.

2.

Patel, Eshan U., Anya M. Litvak, S P Leitner, et al.. (2023). 133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC). ESMO Open. 8(1). 101472–101472. 1 indexed citations

3.

Molinari, Chiara, Giorgia Marisi, George Laliotis, et al.. (2023). 590P Assessment of circulating tumor (ct)DNA in patients (pts) with locally advanced rectal cancer (LARC) pts treated with neoadjuvant therapy (NAT). Annals of Oncology. 34. S428–S428. 4 indexed citations

4.

Lucci, Anthony, Somasundaram Addanki, Ekaterina Kalashnikova, et al.. (2023). 16P Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA. ESMO Open. 8(1). 101240–101240.

5.

Park, Kyong Hwa, Seung Hyun Yong, Hyo Sup Shim, et al.. (2023). MA11.11 Drug Tolerant Persister Cells to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer Harboring EGFR Mutations (NORA). Journal of Thoracic Oncology. 18(11). S140–S141.

6.

Oxnard, Geoffrey R., Eric A. Klein, Michael V. Seiden, et al.. (2019). Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). Annals of Oncology. 30. v912–v912. 25 indexed citations

7.

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2018). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of Oncology. 30(3). 405–411. 460 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact